tldrdailynews.com logo
Tag

Gsk

All articles tagged with #gsk

GSK shifts funds to late-stage R&D, relocates HQ to Cambridge
business28 days ago

GSK shifts funds to late-stage R&D, relocates HQ to Cambridge

GSK unveiled a three-year plan to reallocate resources toward its late-stage R&D and move its research HQ from Stevenage to Cambridge, aiming for 1.9 billion pounds in annual savings by 2029 at a 2.4 billion pound one-time cost. Savings will come mainly from procurement and portfolio shifts from mature products to novel therapies, with no jobs figure disclosed yet, and will fund further pipeline assets such as antibody-drug conjugates as the company counters 2028 dolutegravir patent expiry; the London HQ remains, and a 400 million pound Cambridge investment underscores tighter integration with the UK life sciences ecosystem.

via Fierce Biotech|
#business#cambridge#cost-savings
GSK to buy Nuvalent for $10.6B, adding a multi-asset NSCLC portfolio
business2 months ago

GSK to buy Nuvalent for $10.6B, adding a multi-asset NSCLC portfolio

GSK will acquire Nuvalent for $10.6 billion in cash ($124 per share), gaining three NSCLC programs—zidesamtinib (ROS1) and neladalkib (ALK) as late-stage, potentially best-in-class therapies plus NVL-330 (HER2) and a preclinical portfolio—along with a platform for lung-cancer expansion. The deal, expected to close after regulatory approvals in 2026, is designed to be revenue- accretive from 2027 and-core EPS accretive by 2029 (including synergies and reprioritisation), financed largely by debt and cash with no expected rating impact and maintaining GSK’s dividend policy.

via GSK|
#alk#business#gsk
business2 months ago

Nuvalent soars on GSK deal as Smucker beats, SailPoint slides; chips rebound in premarket

Premarket movers include Nuvalent jumping about 39% after GSK agreed to acquire it for $10.6 billion; J.M. Smucker rose about 3.5% after Q4 results beat estimates; SailPoint fell more than 12% on weaker full-year guidance despite earnings beating expectations; Alibaba edged up roughly 0.9% as the Pentagon added Chinese firms to a military list; Vail Resorts dropped about 4.9% after soft Q3 results, while Micron and Qualcomm helped drive a chip stock rebound in premarket trading.

via CNBC|
#alibaba#business#gsk
GSK to acquire 35Pharma for HS235 to advance pulmonary hypertension therapy
business6 months ago

GSK to acquire 35Pharma for HS235 to advance pulmonary hypertension therapy

GSK will acquire 35Pharma for $950 million in cash, gaining HS235, a potentially best-in-class activin signalling inhibitor in early clinical development for cardiopulmonary diseases including PAH and PH-HFpEF. HS235 aims to reduce bleeding risk and may offer metabolic benefits, expanding GSK’s RI&I portfolio with planned PAH and PH-HFpEF trials; the deal is subject to regulatory approvals.

via GSK|
#35pharma#acquisition#business
GSK to acquire RAPT Therapeutics, adding long-acting anti-IgE for food allergies
business7 months ago

GSK to acquire RAPT Therapeutics, adding long-acting anti-IgE for food allergies

GSK has agreed to buy RAPT Therapeutics for $58 per share (~$2.2 billion equity, ~$1.9 billion net) to gain ozureprubart, a long-acting anti-IgE antibody in phase IIb aimed at prophylactic protection against food allergies. The therapy could allow dosing every 12 weeks (vs current injections every 2–4 weeks), addressing a major unmet need and expanding GSK’s allergy portfolio. The deal is structured as a tender offer with closing expected in Q1 2026, and includes milestone/royalty arrangements linked to RAPT’s partner.

via GSK|
#anti-ige#business#food-allergies
GSK’s Blenrep Gains US FDA Approval for Blood Cancer Treatment
healthcare10 months ago

GSK’s Blenrep Gains US FDA Approval for Blood Cancer Treatment

The US FDA has approved GSK's Blenrep in combination with bortezomib and dexamethasone for treating relapsed/refractory multiple myeloma in patients who have received at least two prior therapies, based on positive results from the DREAMM-7 trial showing significant survival benefits. Blenrep is notable for its community accessibility and ongoing development in earlier treatment lines.

via GSK|
#blenrep#cancer-treatment#fda-approval
GSK CEO Emma Walmsley to Step Down, Insider Miels to Succeed
business11 months ago

GSK CEO Emma Walmsley to Step Down, Insider Miels to Succeed

GSK's CEO Emma Walmsley will step down at the end of the year and be replaced by insider Luke Miels, as the company aims to accelerate its pipeline and navigate a challenging global environment. The leadership change has been well received by investors, with Miels expected to focus on delivering GSK's growth targets amid geopolitical and market uncertainties.

via Reuters|
#business#ceo-transition#emma-walmsley
business11 months ago

GSK CEO Walmsley to Step Down, Miels to Succeed Amid Stock Rally

Emma Walmsley, the first woman to lead a major pharmaceutical company, will step down as CEO of GSK on December 31 after over eight years, with Luke Miels set to succeed her. Despite strategic successes like spinning off Haleon, GSK's share performance has been underwhelming, with only modest growth and a significant decline since Walmsley's appointment.

via ABC News - Breaking News, Latest News and Videos|
#business#ceo-change#emma-walmsley